Evidence map›Paper›PMID 35116240›Full record

ArticleTranslational cancer research2021

CD276 (B7H3) improve cancer stem cells formation in cervical carcinoma cell lines.

Jianfeng Shi, Haishan Zhao, Huan Lian, Linnan Ke, Lei Zhao, Chunren Wang, Qianqian Han

Erratum issuedOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jianfeng Shi *Division of Biomaterials, Department of Medical Devices, Chinese National Institutes for Food and Drug Control, Beijing, China.
Haishan Zhao *Guangdong Provincial Key Laboratory of South China Structural Heart Disease, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangzhou, China.
Huan LianDivision of Biomaterials, Department of Medical Devices, Chinese National Institutes for Food and Drug Control, Beijing, China.
Linnan KeDivision of Biomaterials, Department of Medical Devices, Chinese National Institutes for Food and Drug Control, Beijing, China.
Lei ZhaoDivision of Biomaterials, Department of Medical Devices, Chinese National Institutes for Food and Drug Control, Beijing, China.
Chunren WangDivision of Biomaterials, Department of Medical Devices, Chinese National Institutes for Food and Drug Control, Beijing, China.
Qianqian HanDivision of Biomaterials, Department of Medical Devices, Chinese National Institutes for Food and Drug Control, Beijing, China.
National Institutes for Food and Drug Control · CNGuangdong Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer stem cells (CSCs) have been considered as a potential therapeutic target for cervical carcinoma. CD 276 is a well-known immune check point molecular, but its relationship with cervical CSCs was still unclear.

methodsHeLa cell lines were obtained as cervical carcinoma

resultsHere, we demonstrate that the expression of CD276 is positively correlated with the amount of sphere-forming cells in HeLa cell lines. Overexpression of CD276 causes the inhibition of HeLa cells' sphere formation, colony formation and cell viability. Meanwhile, the downregulation of CD276 leads to the other way. We also demonstrate that CD276 contributes to the chemotherapy resistance in the cell line. Furthermore, we verify the CD276's function on HeLa xenotransplantation mice model.

conclusionsThese results suggest that CD276 elevates the self-renewal capacity of HeLa CSCs.

Indexed as

cancer stem cells (CSCs)CD276cervical carcinomaHeLa cellssphere formation cells

Identifiers

PMID35116240
PMCPMC8798926
OpenAlexW3127230438

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.